A major breakthrough in treating diffuse large B-cell lymphoma – Mount Sinai Department of Medicine
Mount Sinai shared a post on LinkedIn:
“An international team led by Joshua Brody, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai, has made a major breakthrough in treating diffuse large B-cell lymphoma (DLBCL) – the most common type of non-Hodgkin lymphoma.
In the EPCORE NHL-2 clinical trial, researchers combined chemotherapy with immunotherapy, achieving higher complete remission rates than either treatment alone. These findings, published in Blood, offer new hope for patients whose lymphoma has returned or has not responded to standard treatments.
“For patients whose first treatments don’t work, options have been limited,” said Dr. Brody. “This study shows that combining immunotherapy with chemotherapy can significantly improve outcomes and help more patients achieve remission.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023